Inhaled glucocorticoids: New developments relevant to updating of the Asthma Management Guidelines

Respiratory Medicine

Volumn 90, Issue 7, 1996, Pages 379-384

  Barnes, P J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID;

ASTHMA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG POTENCY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; NEBULIZATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; TOPICAL DRUG ADMINISTRATION;

EID: 0029763908     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(96)90108-0     Document Type: Review

References (44)

1. Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone proprionate. Drugs 1994; 47: 318-331.
2. Phillips GH. Structure-activity relationships of topically active steroids: the selection of fluticasone proprionate. Respir Med 1994; 84 (Suppl. A): 19-23.
3. Högger P, Rohdewald P. Binding kinetics of fluticasone proprionate to the human glucocorticoid receptor. Steroids 1994; 59: 597-602.
4. Harding SM. The human pharmacology of fluticasone diproprionate. Respir Med 1990; 84 (Suppl. A); 25-29.
5. Barnes PJ, Pedersen S. Efficacy and safety of inhaled steroids in asthma. Am Rev Respir Dis 1993; 148: S1-S26.
6. Lipworth BJ. New perspectives in drug delivery and systemic bioactivity. Thorax 1995; 50: 105-110.
7. Barnes PJ. Inhaled glucocorticoids for asthma. New Engl J Med 1995; 332: 868-875.
8. Anderson N, Klint S, Randwall G et al. Equipotency of budesonide and fluticasone proprionate in the vasoconstriction assay. Am J Respir Crit Care 1994; 149: A467.
9. English AF, Neate MS, Quint DJ. Biological activities of some corticosteroids used in asthma. Am J Respir Crit Care Med 1994; 149: A212.
10. Miller LA, Mattsson H, Ohlsion D. Prolonged release from the airway tissue of glucocorticoids budesonide and fluticasone proprionate as compared to beclomethasone diproprionate and hydrocortisone. Am J Respir Crit Care Med 1994; 149: A966.
11. -1) administered by pressurized inhaler. Respir Med 1993; 87: 609-620.
12. Fabbri L, Burge PS, Croonenburgh L et al. Comparison of fluticasone proprionate with beclomethasone diproprionate in moderate to severe asthma treated for one year. Thorax 1993; 48: 817-823.
13. Dahl R, Lundbacr B, Malo J et al. A dose-ranging study of fluticasone proprionate in adult patients with moderate asthma. Chest 1993; 104: 1352-1358.
14. Barnes NC. A multi-centre, randomised, double-blind, parallel-group study to compare fluticasone proprionate (FP) 1 mg daily with beclomethasone diproprionate (BDP) 2 mg daily in adult patients with severe asthma. Am Rev Respir Dis 1992; 145: A743.
15. Gustafsson P, Tsanakas J, Gold M, Primhar R, Radford M, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone proprionate 200 μg/day with inhaled beclomethasone diproprionate 400 mg/day in mild and moderate asthma. Arch Dis Child 1993; 19: 206-211.
16. Leblanc P, Mink S, Keistinen T, Saaelainen PA, Ringdal N, Payne SL. A comparison of fluticasone proprionate 200 mg/day with beclomethasone diproprionate 400 μg/ day in adult asthma. Allergy 1994; 49: 380-385.
17. Lundback B, Dahl R, de Jonghe M, Hyderbrendt N, Valta R, Payne SL. A comparison of fluticasone proprionate when delivered by either the metered-dose inhaler or the Diskhaler in the treatment of mild-to-moderate asthma. Eur J Clin Res 1994; 5: 11-19.
18. Conolly A. A comparison of fluticasone proprionate 100 μg twice daily with budesonide 200 μg twice daily via their respective powder devices in the treatment of asthma. Eur J Clin Res 1995; 7: 15-29.
19. Ayers JG, Bateman ED, Lundback B, Harris TAJ. High dose fluticasone proprionate, 1 mg daily, versus fluticasone proprionate, 2 mg daily, or budesonide 1·6 mg daily in patients with chronic severe asthma. Eur Resp J 1995.
20. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982; 63 (Suppl. 122): 86-95.
21. Chervansky P, van As A, Bronsky EA et al. Fluticasone proprionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994; 94: 676-683.
22. Boe J, Bakke P, Rodolen T, Skovlund E, Gulsvik A. high dose inhaled steroids in asthmatics: moderate efficacy gain and oppression of the hypethalamic-pituitary-adrenal (HPA) axis. Eur Resp J 1994; 7: 2179-2189.
23. Granén A, Eckernäs S, Brudin RM, Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 1994; 38: 521-525.
24. Grove A, Allam C, McCarlane LC, McPhate G, Jackson CM, Lipworth BJ. A comparison of the systemic bioavailability of inhaled budesonide and fluticasone proprionate in normal subjects. Br J Clin Pharmacol 1994; 38: 527-532.
25. Pedersen S, Ramsgaard-Hansen O, Nikander K. Budesonide suspension for nebulisation in children with asthma. Eur Respir J 1989; 2: 647S.
26. Ilangovan P, Pedersen S, Godfrey S, Nikander K, Novisky N, Warner JO. Nebulised budesonide suspension in severe steroid-dependent preschool asthma. Arch Dis Child 1993; 68: 356-359.
27. de Blic J, Delacourt C, le Bourgeois M, Mahut B, Allouche J, Scheinmann P. A double-blind parallel group study of nebulised budesonide in severe infantile asthma. Am Rev Respir Dis 1993; 147: A266.
28. Grimfeld A, Lesbros D. Long-term study of nebulised budesonide in young children with moderate to severe asthma. Eur Respir J 1994; 7: 27S.
29. Otulana BA, Varma N, Bullock A, Higenbottam T. High dose nebulized steroid in the treatment of chronic steroid-dependent asthma. Respir Med 1992; 86: 105-108.
30. Higenbottam TW, Clark RA, Luksza AR et al. The role of nebulised budesonide in permitting a reduction in the dose of oral steroid in persistent severe asthma. Eur J Clin Res 1994; 5: 1-10.
31. Brown PH, Greening AP, Crompton GK. Large volume spacer devices and the influence of high dose beclomethasone diproprionate on hypothalamo-pituitary-adrenal axis function. Thorax 1993; 48: 233-238.
32. Selroos O, Halme M. Effect of a Volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered-dose inhaler and dry powder inhaler. Thorax 1991; 46: 891-894.
33. Thorsson L, Edsbäcker S, Conradson T. Lung deposition of budesonide from Turbohaler R is twice that from a pressurized metered-dose inhaler P-MDI. Eur Resp J 1994; 7: 1839-1844.
34. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 5: 369-372.
35. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993; 65: 130-133.
36. Selroos O, Backman R, Forsen K et al. Clinical efficacy of budesonide Turbuhaler compared with that of beclomethasone diproprionate PMDI with volumatic spacer. Allergy 1994; 49: 833-836.
37. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993; 147: 697-704.
38. Haahtela T, Jarvinen M, Kava T et al. Comparison of a b2-agonist terbutaline with an inhaled steroid in newly detected asthma. New Engl J Med 1991; 325: 388-392.
39. Haahtela T, Järvinsen M, Kava T et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. New Engl J Med 1994; 331: 700-705.
40. Selroos O, Backman R, Forsen K et al. When to start treatment of asthma with inhaled steroids? Eur Resp J 1994; 7 (suppl 18): 151S.
41. International Consensus Report on Diagnosis and Management of Asthma. Clin Exp Allergy 1992; 22 (Suppl. 1): 1-72.
42. Levy ML, Stevenson IC. A comparison of the efficacy of inhaled fluticasone proprionate 2 mg daily and a reducing course of oral prednisolone in the treatment of acute exacerbations of asthma. Am J Respir Crit Care Med 1995; 151: A276.
43. Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 1991; 143: 1317-1321.
44. Waalkens HJ, van Essen-Zandvliet EE, Hughes MD et al. Cessation of long-term treatment with inhaled corticosteroids (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis 1993; 148; 1252-1257.